Skip to main content
Journal cover image

Molecular markers for incidence, prognosis, and response to therapy.

Publication ,  Journal Article
Tong, BC; Harpole, DH
Published in: Surg Oncol Clin N Am
January 2012

Lung cancer is the most common malignancy in the United States and worldwide. In 2011, it is estimated that more than 221,000 people in the United States will be diagnosed with cancer of the lung and bronchus. For patients with early-stage disease, 5-year survival approaches only 50%. Recent advances using molecular, genetic, and proteomic profiling of lung tumors have enabled refining the prognosis for patients with non-small cell lung cancer. With targeted therapies, there is an opportunity to enhance long-term survival. This article discusses several key molecular markers used in the prognostication and treatment of non-small cell lung cancer.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Surg Oncol Clin N Am

DOI

EISSN

1558-5042

Publication Date

January 2012

Volume

21

Issue

1

Start / End Page

161 / 175

Location

United States

Related Subject Headings

  • Vascular Endothelial Growth Factor A
  • Receptor Protein-Tyrosine Kinases
  • Proteomics
  • Protein-Tyrosine Kinases
  • Prognosis
  • Precision Medicine
  • Oncology & Carcinogenesis
  • Microarray Analysis
  • MicroRNAs
  • Lung Neoplasms
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Tong, B. C., & Harpole, D. H. (2012). Molecular markers for incidence, prognosis, and response to therapy. Surg Oncol Clin N Am, 21(1), 161–175. https://doi.org/10.1016/j.soc.2011.09.007
Tong, Betty C., and David H. Harpole. “Molecular markers for incidence, prognosis, and response to therapy.Surg Oncol Clin N Am 21, no. 1 (January 2012): 161–75. https://doi.org/10.1016/j.soc.2011.09.007.
Tong BC, Harpole DH. Molecular markers for incidence, prognosis, and response to therapy. Surg Oncol Clin N Am. 2012 Jan;21(1):161–75.
Tong, Betty C., and David H. Harpole. “Molecular markers for incidence, prognosis, and response to therapy.Surg Oncol Clin N Am, vol. 21, no. 1, Jan. 2012, pp. 161–75. Pubmed, doi:10.1016/j.soc.2011.09.007.
Tong BC, Harpole DH. Molecular markers for incidence, prognosis, and response to therapy. Surg Oncol Clin N Am. 2012 Jan;21(1):161–175.
Journal cover image

Published In

Surg Oncol Clin N Am

DOI

EISSN

1558-5042

Publication Date

January 2012

Volume

21

Issue

1

Start / End Page

161 / 175

Location

United States

Related Subject Headings

  • Vascular Endothelial Growth Factor A
  • Receptor Protein-Tyrosine Kinases
  • Proteomics
  • Protein-Tyrosine Kinases
  • Prognosis
  • Precision Medicine
  • Oncology & Carcinogenesis
  • Microarray Analysis
  • MicroRNAs
  • Lung Neoplasms